Moriguchi Lab
The technology for mechanical circulatory support devices designed to assist patients with end-stage heart failure or experiencing cardiogenic shock is advancing rapidly. The Moriguchi Lab leads research initiatives to improve the selection, treatment and management of patients in need of temporary or durable mechanical support, including the total artificial heart.
Personal Statement
As director of the MCS program at Cedars-Sinai Smidt Heart Institute, I have worked to ensure access to the benefits of mechanical circulatory support for patients with end-stage heart disease/cardiogenic shock either as bridge to transplant or destination (alternative to transplant) therapy. We have participated in numerous clinical investigations resulting in a variety of presentations, abstracts and manuscripts at national and international meetings that have contributed to the knowledge and experience of this rapidly growing field.
Jaime Moriguchi
Breakthrough Research
- This rapidly growing field addresses advanced options for cardiovascular support using temporary MCS devices, including ECMO, Impellas, intra-aortic balloon pumps and various other forms of intravascular and extracorporeal support systems. I have studied the outcomes and hemodynamic roles resulting from the use of these devices in end stage heart failure and cardiogenic shock.
- The total artificial heart represents the only definitive mechanical therapy for severe, end-stage biventricular heart failure. Its complexities in selection, outcomes and adverse events, limit its use to few medical centers across the world. I have extensive experience in the utilization and management of these devices and as such continue to investigate its role in the management of patients.
Publications
Learn more about the recent research publications from the Moriguchi Lab.
Collaborations
The Moriguchi Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.